Stem Cell Therapy in China 2026: First Drug Approved, New Regulations, What Patients Need to Know

China's stem cell therapy landscape has transformed dramatically in the past year. In 2025, the country approved its first domestically developed stem cell drug and enacted its first comprehensive regulation — Decree No. 818 — which took effect in May 2026. This is a pivotal moment for international patients considering stem cell treatment in China.

Let me break down what's changed and what patients need to know.

The Landmark Approval: China's First Stem Cell Drug

In June 2025, China's National Medical Products Administration (NMPA) approved Aimmatoce Injection (睿铂生/艾米迈托赛注射液) — the country's first domestically developed stem cell drug. It's an umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy for steroid-refractory acute graft-versus-host disease (aGVHD).

Pricing: ¥19,800 per dose (~$2,700 USD). A full course of 8 doses runs approximately ¥158,000 (~$21,600). For context, the US equivalent (Ryoncil) costs around $1.55 million for 8 doses — China's version is roughly 1/70th the price. (Sources: phirda.com, China Daily)

The New Regulatory Framework: Decree 818

Decree No. 818 (《生物医学新技术临床研究和临床转化应用管理条例》), signed in September 2025 and effective May 1, 2026, is China's first comprehensive regulation for stem cells, gene editing, CAR-T, and tissue engineering. Here's what matters for international patients:

Three Key Rules

Clinical research cannot charge patients: Legitimate clinical research must be free. If a clinic charges you for a "research" stem cell treatment, it's illegal. (Article 20)
Dual-track approval system: Treatments are approved either as "drugs" (via NMPA) or "medical technologies" (via National Health Commission). Both pathways are regulated.
Only Grade 3A hospitals can conduct stem cell clinical work: Top-tier hospitals only. This eliminates unlicensed clinics.

What Treatments Are Available Now?

Treatment	Cost in China	Status	Notes
Aimmatoce (MSC for aGVHD)	¥19,800/dose (~$2,700)	Approved drug (NMPA)	Available at major hospitals, full course ~$21,600
MSC for knee osteoarthritis	~¥36,000/session (~$4,900)	Approved tech (Hainan Boao)	For severe OA unresponsive to standard therapy
Autologous lung cell transplant	~¥150,000 (~$20,500)	Approved tech (Hainan Boao)	For lung fibrosis / chronic lung disease
MSC for ischemic heart disease	~¥60,000 (~$8,200)	Approved tech (Hainan Boao)	For significant left ventricular dysfunction
Clinical trials (various indications)	Free (by law)	Phase I-III trials	167 IND applications approved; must be at Grade 3A hospital

Sources: China NMPA, Hainan Boao Lecheng Pilot Zone, published fee schedules (2025-2026). Prices subject to change.

How to Access Stem Cell Therapy Safely in China

If you're considering stem cell treatment in China, here's the safe path:

Target the right pathway: Only pursue treatments that are either an NMPA-approved drug or an NHC-approved medical technology at a regulated hospital.
Go to a Grade 3A hospital: Only China's top-tier hospitals are legally permitted to provide stem cell treatments. Examples include Peking University People's Hospital, Beijing Jishuitan Hospital, Tongji Hospital (Wuhan), and the hospitals in the Hainan Boao Lecheng Medical Zone.
Consider the Hainan Boao Pilot Zone: This is China's designated medical tourism zone, with streamlined access for international patients and approved stem cell therapies available.
Verify the pricing upfront: Legitimate treatments have a clear fee schedule. Ask for a written cost estimate.
Be extremely cautious about unlicensed clinics: Multiple clinics have been shut down in 2025-2026 for illegal stem cell practices, including cases in Wuhan, Hainan, Shanghai, and Tianjin with fines up to ¥2 million.

What's Coming: Pipeline Outlook

As of December 2025, China had 215 stem cell drug IND applications submitted, with 167 approved for clinical trials. Shanghai and Beijing lead with 30 INDs each. Dominant cell type: mesenchymal stem cells (73.6% of INDs). Key indications in Phase III include knee osteoarthritis, liver failure, refractory anal fistula, and heart failure. Multiple approvals are expected through 2026-2027. (Source: BIOCHINA2026)

Important Warning for International Patients

Under Decree 818, which took effect May 1, 2026, legitimate clinical research cannot charge patients any fees. This means that any clinic offering "stem cell research participation" for a fee is operating illegally. Enforcement has been aggressive — several clinics have already been fined and shut down in 2025-2026. If you're paying for stem cell treatment in China, make sure it's for an approved clinical application, not a research study.

The Bottom Line

China has transformed from a poorly regulated market into a structured, affordable destination for stem cell therapy. With the first approved drug priced at 1/70th of the US equivalent, a growing pipeline of treatments entering Phase III, and a clear regulatory framework under Decree 818, China offers genuine options for patients who need stem cell treatments they cannot afford at home. The key is using regulated channels — Grade 3A hospitals or the Hainan Boao pilot zone — and avoiding unlicensed operators.